Inspection Record

Daizo Corporation — FDA 483 Findings

US FDAInspected 2023-11-06Published 2025-03-06 3 findingsLaboratory and QC controlsComputer system validation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

2Laboratory and QC controls

Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.

3Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

About this record

Extracted automatically from the document US FDA published on 2025-03-06. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Daizo Corporation company profile — full history US FDA documents, 2025 Go to Findings search